Alfentanil pharmacokinetics in patients with cirrhosis. 1985

C Ferrier, and J Marty, and Y Bouffard, and J P Haberer, and J C Levron, and P Duvaldestin

The pharmacokinetics of alfentanil were studied in 11 patients with alcoholic cirrhosis and 10 control patients during general anesthesia. All patients received 50 micrograms . kg-1 alfentanil as an intravenous bolus injection. Plasma concentrations were measured at intervals up to 10 h, using a specific radioimmunoassay technique. Protein binding was measured by equilibrium dialysis. Patients with cirrhosis had a significantly lower (P less than 0.01) plasma clearance of alfentanil of 1.6 +/- 1.0 ml . min-1 . kg-1 (mean +/- SD) instead of 3.1 +/- 1.6 ml . min-1 . kg-1 in the controls. The total apparent volume of distribution was similar in the two groups. The elimination half-life was prolonged from 90 +/- 18 min in the controls to 219 +/- 128 min in the cirrhotics (P less than 0.01). Patients with cirrhosis had a higher (P less than 0.01) alfentanil plasma-free fraction (18.6 +/- 9.4%) compared with the control patients (11.5 +/- 3.9%). When kinetic parameters were corrected for protein binding, the unbound volume of distribution and the free drug clearance were decreased significantly in patients with cirrhosis. Since the concentration alpha 1-glycoprotein to which alfentanil mainly is bound in plasma did not differ in the two groups, it is suggested that the increase in the free fraction is caused by an alteration of binding sites of this protein in patients with cirrhosis. Owing to its delayed elimination and increased free fraction, alfentanil will exert a prolonged and pronounced effect in patients with cirrhosis.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008104 Liver Cirrhosis, Alcoholic FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING. Alcoholic Cirrhosis,Hepatic Cirrhosis, Alcoholic,Alcoholic Hepatic Cirrhosis,Alcoholic Liver Cirrhosis
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum

Related Publications

C Ferrier, and J Marty, and Y Bouffard, and J P Haberer, and J C Levron, and P Duvaldestin
January 2007, Clinical pharmacokinetics,
C Ferrier, and J Marty, and Y Bouffard, and J P Haberer, and J C Levron, and P Duvaldestin
February 1994, Anesthesia and analgesia,
C Ferrier, and J Marty, and Y Bouffard, and J P Haberer, and J C Levron, and P Duvaldestin
June 1987, British journal of anaesthesia,
C Ferrier, and J Marty, and Y Bouffard, and J P Haberer, and J C Levron, and P Duvaldestin
January 1991, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
C Ferrier, and J Marty, and Y Bouffard, and J P Haberer, and J C Levron, and P Duvaldestin
January 1986, Journal of clinical pharmacology,
C Ferrier, and J Marty, and Y Bouffard, and J P Haberer, and J C Levron, and P Duvaldestin
January 1989, Anesthesia and analgesia,
C Ferrier, and J Marty, and Y Bouffard, and J P Haberer, and J C Levron, and P Duvaldestin
August 1983, Anesthesiology,
C Ferrier, and J Marty, and Y Bouffard, and J P Haberer, and J C Levron, and P Duvaldestin
October 1987, British journal of clinical pharmacology,
C Ferrier, and J Marty, and Y Bouffard, and J P Haberer, and J C Levron, and P Duvaldestin
August 1982, Anesthesia and analgesia,
C Ferrier, and J Marty, and Y Bouffard, and J P Haberer, and J C Levron, and P Duvaldestin
April 1990, Archives of disease in childhood,
Copied contents to your clipboard!